Stockscreener 앱 받기
1.54%
시간 외 거래:
전일 마감가:
$1.30
열려 있는:
$1.29
하루 거래량:
11.31M
Relative Volume:
1.04
시가총액:
$815.25M
수익:
$29.48M
순이익/손실:
$-201.19M
주가수익비율:
-4.00
EPS:
-0.32
순현금흐름:
$-216.50M
1주 성능:
+9.40%
1개월 성능:
-7.91%
6개월 성능:
-56.31%
1년 성능:
-72.17%
1일 변동 폭
$1.26
$1.33
1주일 범위
$1.1603
$1.43
52주 변동 폭
$1.09
$4.84
제론 Stock (GERN) Company Profile
명칭
Geron Corp
전화
(650) 473-7700
주소
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
GERN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.28 | 885.32M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
제론 Stock (GERN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-05-08 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 개시 | Leerink Partners | Outperform |
| 2024-04-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 개시 | TD Cowen | Buy |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2023-09-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-28 | 개시 | Goldman | Neutral |
| 2022-10-28 | 개시 | Wedbush | Outperform |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2021-11-02 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 재개 | B. Riley Securities | Buy |
| 2020-08-03 | 개시 | Stifel | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-09-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-04-09 | 업그레이드 | Needham | Hold → Buy |
| 2019-01-31 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 재확인 | FBR & Co. | Outperform |
| 2016-09-13 | 재확인 | FBR Capital | Outperform |
| 2015-12-07 | 재확인 | Piper Jaffray | Overweight |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-06-12 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-03-12 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2013-12-10 | 재확인 | MLV & Co | Buy |
| 2013-12-10 | 업그레이드 | Needham | Hold → Buy |
| 2013-11-08 | 재확인 | MLV & Co | Buy |
| 2013-10-16 | 개시 | MLV & Co | Buy |
| 2012-08-30 | 개시 | Stifel Nicolaus | Buy |
| 2012-06-28 | 개시 | Needham | Hold |
모두보기
제론 주식(GERN)의 최신 뉴스
Geron's New CEO Receives Massive 11M Share Options Grant Worth $14.3M at Current Price - Stock Titan
Geron: I Think We've Seen This Movie Before (NASDAQ:GERN) - Seeking Alpha
A Quick Look at Today's Ratings for Geron(GERN.US), With a Forecast Between $4 to $5 - 富途牛牛
Geron Corporation (NASDAQ:GERN) Q2 2025 Earnings Call Transcript - Insider Monkey
Geron: Q2 Earnings Snapshot - Huron Daily Tribune
Geron Corp (GERN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Geron (GERN) Q2 Revenue Jumps 5,477% - sharewise.com
Semerjian to lead Geron - biocentury.com
Geron reports Q2 EPS (2c), consensus (3c) - TipRanks
Earnings call transcript: Geron surpasses Q2 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Geron surpasses Q2 2025 forecasts, stock rises - Investing.com
Geron appoints Harout Semerjian as CEO - TipRanks
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Geron Q2 2025 presentation: RYTELO sales climb 24%, stock jumps premarket - Investing.com
Geron earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Geron earnings beat, revenue topped estimates - Investing.com
Geron appoints Harout Semerjian as new CEO amid RYTELO expansion - Investing.com
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Stock Titan
Geron Taps Former Novartis Hematology Leader as CEO: 30-Year Expert to Scale RYTELO Commercial Launch - Stock Titan
What is the dividend policy of Geron Corporation stockUnlock daily trading alerts for profits - Jammu Links News
What makes Geron Corporation stock price move sharplyExtraordinary earning power - Jammu Links News
Ball Corp Set to Report Q2 Earnings: What Lies Ahead for the Stock? - The Globe and Mail
Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) With a $3 PT - Insider Monkey
Commercial Stage Biotech Geron Sets Q2 Earnings Release: Key Financial Updates Coming August 6 - Stock Titan
How high can Geron Corporation stock price go in 2025Real Time Stock Signal - metal.it
What is the risk reward ratio of investing in Geron Corporation stockGet timely market insights for better trades - Jammu Links News
How volatile is Geron Corporation stock compared to the marketDynamic growth stocks - Jammu Links News
Geron (GERN.O) Surges 5.08%: What’s Driving the Intraday Rally? - AInvest
What analysts say about Geron Corporation stockOutstanding stock performance - jammulinksnews.com
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 - BioSpace
Market Sentiment Around Loss-Making Geron Corporation (NASDAQ:GERN) - simplywall.st
Geron Corporation Stock Analysis and ForecastOutstanding capital returns - jammulinksnews.com
Geron Corporation (GERN) Plunges 3.88% to 2025 Low on Earnings Miss - AInvest
Commercial Stage Biotech Geron Expands Team with 342,000 Share Equity Package for Strategic New Hires - Stock Titan
Why Geron Corporation stock attracts strong analyst attentionTechnical Breakout List - Newser
Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Geron (NASDAQ:GERN) Shares Gap Down – Here’s Why - Defense World
Cambridge Investment Research Advisors Inc. Cuts Stock Position in Geron Corporation (NASDAQ:GERN) - Defense World
Here’s Why Geron Corp. (NASDAQ:GERN) Crashed Today - MSN
Geron resumed with a Sell at Goldman Sachs - TipRanks
Geron Corp’s Rytelo Faces Market Challenges and Declining Physician Adoption, Supporting Sell Rating - TipRanks
Goldman Sachs resumes Geron stock coverage with Sell rating on weak Rytelo sales - Investing.com
Geron Corp (GERN) Stock: A Year of Highs and Lows - investchronicle.com
Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) - MSN
13 Stocks Under $5 With High Upside Potential - Insider Monkey
DSS switches auditors to HTL; no disputes with Grassi reported | GERN SEC FilingForm 4 - Stock Titan
Geron Corporation(NasdaqGS: GERN) dropped from Russell 2500 Value Index - MarketScreener
Geron Corporation(NasdaqGS: GERN) dropped from Russell Small Cap Comp Value Index - MarketScreener
With 65% institutional ownership, Geron Corporation (NASDAQ:GERN) is a favorite amongst the big guns - Yahoo Finance
Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade) (NASDAQ:GERN) - Seeking Alpha
제론 (GERN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):